CAJ | 학술논문

目的观察恶性肿瘤再程放疗的疗效。方法回顾性分析29例接受再程放疗的患者，其中食管癌15例，鼻咽癌5例，椎体转移癌3例，宫颈癌、直肠癌、鼻腔NK/T细胞淋巴瘤、脑转移癌、髓母细胞瘤和脑胶质瘤各1例，肿瘤靶区剂量30~50Gy/10~25f。结果对存在可评价病灶者，在放疗结束后取得完全缓解(CR)者为38.5%(10例/26例)，部分缓解(PR)为46.2%(12例/26例)，1例(3.8%)稳定(SD)，2例(7.7%)PD，1人未评估。无进展生存期为4~36个月，中位时间8个月，1年的无进展生存率(PFS)为65%。严重的急性和晚期放射反应发生率分别为6.9%。结论再程放疗安全、有效。
목적관찰악성종류재정방료적료효。방법회고성분석29례접수재정방료적환자，기중식관암15례，비인암5례，추체전이암3례，궁경암、직장암、비강NK/T세포림파류、뇌전이암、수모세포류화뇌효질류각1례，종류파구제량30~50Gy/10~25f。결과대존재가평개병조자，재방료결속후취득완전완해(CR)자위38.5%(10례/26례)，부분완해(PR)위46.2%(12례/26례)，1례(3.8%)은정(SD)，2례(7.7%)PD，1인미평고。무진전생존기위4~36개월，중위시간8개월，1년적무진전생존솔(PFS)위65%。엄중적급성화만기방사반응발생솔분별위6.9%。결론재정방료안전、유효。
To observe the effectiveness of re-irradiation for malignant tumor.Methods 29 paitents with malignant tumor re-irradiated were enrol ed,in whom 15 patients with esophageal cancer,5 with nasopharyngeal cancer,3 with spinal bone metastases,one with rectal cancer,one with cervical cancer,one with NK/T lymphoma in nasal cavity,one with metastatic brain tumor,one with medul oblastoma and one with cerebral glioma.The total dose of GTV was 30~50Gy with 2~3Gy per fraction. Results For the 26 evaluable patients,complete response was 38.5%,partial response was 46.2%,stable disease was 3.8% and progress disease was 7.7%.One patient did not receive the evaluation.The median time to progression was 8 months (range:4~36 months),and the 1-year progression free survival was 65%.The severe acute and late adverse events occurred in 6.9%of patients,respectively. Conclusion Re-irradiation was ef ective and showed acceptable toxicity.